136 related articles for article (PubMed ID: 21411801)
1. Determining vancomycin clearance in an overweight and obese population.
Leong JV; Boro MS; Winter M
Am J Health Syst Pharm; 2011 Apr; 68(7):599-603. PubMed ID: 21411801
[TBL] [Abstract][Full Text] [Related]
2. Comparing two predictive methods for determining serum vancomycin concentrations at a Veterans Affairs Medical Center.
Lee E; Winter ME; Boro MS
Am J Health Syst Pharm; 2006 Oct; 63(19):1872-5. PubMed ID: 16990634
[TBL] [Abstract][Full Text] [Related]
3. Vancomycin clearance in overweight and obese patients.
Nix DE; Matthias KR; Erstad BL
Am J Health Syst Pharm; 2011 Oct; 68(19):1776-7; author reply 1777-8. PubMed ID: 21930634
[No Abstract] [Full Text] [Related]
4. Evaluation of initial dofetilide dosing recommendation based on actual body weight in overweight and obese patients.
Cao DX; Kohatsu A; Eng L; Mei K; Dinh J; Mok I; Moreau N; Le A; Shin J
J Clin Pharm Ther; 2015 Dec; 40(6):635-9. PubMed ID: 26365492
[TBL] [Abstract][Full Text] [Related]
5. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique.
Vance-Bryan K; Guay DR; Gilliland SS; Rodvold KA; Rotschafer JC
Antimicrob Agents Chemother; 1993 Mar; 37(3):436-40. PubMed ID: 8460912
[TBL] [Abstract][Full Text] [Related]
6. Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1-18 Years.
Smit C; Goulooze SC; Brüggemann RJM; Sherwin CM; Knibbe CAJ
AAPS J; 2021 Apr; 23(3):53. PubMed ID: 33839974
[TBL] [Abstract][Full Text] [Related]
7. Vancomycin pharmacokinetics in middle-aged and elderly men.
Leonard AE; Boro MS
Am J Hosp Pharm; 1994 Mar; 51(6):798-800. PubMed ID: 8010319
[TBL] [Abstract][Full Text] [Related]
8. The association of elevated trough serum vancomycin concentrations with obesity.
Richardson J; Scheetz M; O'Donnell EP
J Infect Chemother; 2015 Jul; 21(7):507-11. PubMed ID: 25851852
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring of vancomycin in a morbidly obese patient.
Penzak SR; Gubbins PO; Rodvold KA; Hickerson SL
Ther Drug Monit; 1998 Jun; 20(3):261-5. PubMed ID: 9631922
[TBL] [Abstract][Full Text] [Related]
10. Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation.
Winter MA; Guhr KN; Berg GM
Pharmacotherapy; 2012 Jul; 32(7):604-12. PubMed ID: 22576791
[TBL] [Abstract][Full Text] [Related]
11. An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers.
Nelson WK; Formica RN; Cooper DL; Schwartz PE; Rutherford TJ
J Oncol Pharm Pract; 2012 Sep; 18(3):323-32. PubMed ID: 22331238
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin trough concentrations in overweight or obese pediatric patients.
Heble DE; McPherson C; Nelson MP; Hunstad DA
Pharmacotherapy; 2013 Dec; 33(12):1273-7. PubMed ID: 23798327
[TBL] [Abstract][Full Text] [Related]
13. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight.
Ducharme MP; Slaughter RL; Edwards DJ
Ther Drug Monit; 1994 Oct; 16(5):513-8. PubMed ID: 7846752
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
Pai MP; Cojutti P; Pea F
Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
Adane ED; Herald M; Koura F
Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
[TBL] [Abstract][Full Text] [Related]
16. Dosing of vancomycin in patients with continuous-flow left ventricular assist devices: a clinical pharmacokinetic analysis.
Jennings DL; Makowski CT; Chambers RM; Lanfear DE
Int J Artif Organs; 2014 Mar; 37(3):270-4. PubMed ID: 24619894
[TBL] [Abstract][Full Text] [Related]
17. Vancomycin Dosing Considerations in a Real-World Cohort of Obese and Extremely Obese Patients.
Morrill HJ; Caffrey AR; Noh E; LaPlante KL
Pharmacotherapy; 2015 Sep; 35(9):869-75. PubMed ID: 26343549
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin Clearance in Obese Adults is not Predictive of Clearance in Obese Adolescents.
Zhang T; Smit C; Sherwin CMT; Knibbe CAJ; Krekels EHJ
Clin Pharmacokinet; 2023 May; 62(5):749-759. PubMed ID: 37017883
[TBL] [Abstract][Full Text] [Related]
19. Vancomycin dosage in overweight and obese children.
Miller M; Miller JL; Hagemann TM; Harrison D; Chavez-Bueno S; Johnson PN
Am J Health Syst Pharm; 2011 Nov; 68(21):2062-8. PubMed ID: 22011985
[TBL] [Abstract][Full Text] [Related]
20. Vancomycin dosing in obese pediatric patients.
Moffett BS; Kim S; Edwards MS
Clin Pediatr (Phila); 2011 May; 50(5):442-6. PubMed ID: 21282257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
